The effect of cyclosporin A on morphine tolerance and dependence: Involvement of L-arginine/nitric oxide pathway

European Journal of Pharmacology

Volumn 452, Issue 1, 2002, Pages 67-75

  Homayoun, Houman ^a   Khavandgar, Simin ^a   Namiranian, Khodadad ^a   Dehpour, Ahmad Reza ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

(Mouse); Antinociception; Cyclosporin A; L Arginine; L NAME (NG nitro L arginine methyl ester); NO (nitric oxide); Opioid dependence tolerance

Indexed keywords

AMINOGUANIDINE; ARGININE; CYCLOSPORIN A; MORPHINE; N(G) NITROARGININE METHYL ESTER; NALOXONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; MALE; MORPHINE ADDICTION; MORPHINE TOLERANCE; MOUSE; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; TAIL FLICK TEST;

ANALGESICS, OPIOID; ANIMALS; ARGININE; CYCLOSPORINE; DRUG TOLERANCE; GUANIDINES; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MORPHINE; MORPHINE DEPENDENCE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; REACTION TIME;

EID: 0037183753     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02243-4     Document Type: Article

References (67)

1. Adams M.L., Kalicki J.M., Meyer E.R., Cicero T.J. Inhibition of the morphine withdrawal syndrome by nitric oxide inhibitor. N-nitro-L-arginine methyl ester. Life Sci. 52:1993;245-249.
2. Al-Shabanah O.A., Alam K., Nagi M.N., Al-Rikabi A.C., Al-Bekairi A.M. Protective effect of aminoguanidine, a nitric oxide synthase inhibitor, against carbon tetrachloride induced hepatotoxicity in mice. Life Sci. 66:2000;265-270.
3. Babey A.M., Kolesnikov Y.A., Cheng J., Inturrisi C.E., Trifilletti R.R., Pasternak G.W. Nitric oxide and opioid tolerance. Neuropharmacology. 33:1994;1463-1470.
4. Berthold H., Borel J.F., Flückiger E. Enigmatic action of cylosporine A on the naloxone-precipitated morphine withdrawal syndrome in mice. Neuroscience. 31:1989;97-103.
5. Bhargava H.N., Bian J.T. Effects of acute administration of L-arginine on morphine antinociception and morphine distribution in central and peripheral tissues of mice. Pharmacol. Biochem. Behav. 61:1998;29-33.
6. Borel J.F., Bauman G., Chapman I., Donatsch P., Fahr A., Mueller E.A., Vigouret J.M. In vivo pharmacological effects of ciclosporin analogues. Adv. Pharmacol. 35:1996;115-246.
7. Brignola G., Calignano A., Di Rosa M. Modulation of morphine antinociception in the mouse by endogenous niric oxide. Br. J. Pharmacol. 113:1994;1372-1376.
8. Cappendijk S.L.T., De Vries R., Dzoljic M.R. Inhibitory effect of nitric oxide (NO) synthase inhibitors on naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Neurosci. Lett. 162:1993;97-100.
9. Conde M., Andrade J., Bedoya F.J., Santa Maria C., Sobrino F. Inhibitory effect of cyclosporin A and FK506 on nitric oxide production by cultured macrophages, evidence of a direct effect on nitric oxide synthase activity. Immunology. 84:1995;476-481.
10. Cuellar B., Fernandez A.P., Lizasoain I., Moro M.A., Lorenzo P., Bentura M.L., Rodrigo J., Leza J.C. Up-regulation of neuronal NO synthase immunoreactivity in opiate dependence and withdrawal. Psychopharmacology. 148:2000;66-73.
11. Dafny N., Wagle V.G., Drath D.B. Cyclosporine alters opiate withdrawal in rodents. Life Sci. 36:1985;1721-1726.
12. G-monomethyl arginine (L-NMMA) and L-arginine on the antinocicpetive effects of morphine in the mouse. Methods Find. Exp. Clin. Pharmacol. 17:1995;577-582.
13. Dambisya Y.M., Lee T.L. Role of nitric oxide in the induction and expression of morphine tolerance and dependence in mice. Br. J. Pharmacol. 117:1996;914-918.
14. Dambisya Y.M., Wong C.L., Chan K. Effects of sympathomimetic agents on opiate analgesia, tolerance and dependence in mice. Methods Find. Clin. Pharmacol. 13:1991;239-248.
15. D'Amour F.E., Smith D.L. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72:1941;74-79.
16. Dawson T.M., Steiner J.P., Dawson V.L., Dinerman J.L., Uhl G.R., Snyder S.H. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 90:1993;9808-9812.
17. Dawson T.M., Steiner J.P., Lyons W.E., Fotuhi M., Blue M., Snyder S.H. The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. Neuroscience. 62:1994;569-580.
18. Dehpour A.R., Akbarloo N., Ghafourifar P. Endogenous nitric oxide modulates naloxone-precipitated withdrawal signs in a mouse model with acute cholestasis. Behav. Pharmacol. 9:1998;77-80.
19. Dougherty P.M., Dafny N. Cyclosporine affects central nervous system opioid activity via direct and indirect means. Brain Behav. Immun. 2:1988;242-253.
20. Dougherty P.M., Aronowski J., Samorajski T., Dafny N. Opiate antinociception is altered by immunemodification: the effects of interferon, cyclosporine and radiation-induced immune suppression upon acute and long-term morphine activity. Brain Res. 385:1986;401-404.
21. Dougherty P.M., Harper C., Dafny N. The effects of alpha-interferon, cyclosporin A, and radiation-induced immune suppression on morphine-induced hypothermia and tolerance. Life Sci. 39:1986;2191-2197.
22. Dougherty P.M., Aronowski J., Drath D., Dafny N. Evidence of neuro-immunologic interactions: cyclosporine modifies opiate withdrawal by effects on the brain and immune components. J. Neuroimmunol. 13:1987;331-342.
23. G-nitro-L-arginine attenuate analgesic tolerance to the mu-opioid morphine but not to the kappa opioids. Pain. 56:1994;69-75.
24. Fecho K., Maslonek K.A., Coussons-Read M.E., Dykstra L.A., Lysle D.T. Macrophage-derived nitric oxide is involved in the depressed concanavalin A responsiveness of splenic lymphocytes from rats administered morphine in vivo. J. Immunol. 152:1994;5845-5850.
25. Fiore C.E., Pennisi P., Cutuli V.M., Prato A., Messina R., Clementi G. L-arginine prevents bone loss and bone collagen breakdown in cyclosporin A-treated rats. Eur. J. Pharmacol. 408:2000;323-326.
26. Fu E., Tz-Chong C., Chiu S.C. Ameliorated effect of L-arginine supplementation on gingival morphology in cyclosporin-treated rats. J. Periodontol. 71:2000;1737-1742.
27. Gyires K. The role of endogenous nitric oxide in the gastroprotective action of morphine. Eur. J. Pharmacol. 255:1994;33-37.
28. Kaibori M., Okumura T., Ito S., Oda M., Inoue T., Kamiyama Y. Inhibition of iNOS induction by FK506, but not by cyclosporine, in rat hepatocytes. Transplant. Proc. 31:1999;804-805.
29. Kikuchi M., Kashii S., Mandai M., Yasuyoshi H., Honda Y., Kaneda K., Akaike A. Protective effects of FK506 against glutamate-induced neurotoxicity in retinal cell culture. Invest. Ophthalmol. Vis. Sci. 39:1998;1227-1232.
30. Kimes A.S., Vaupel D.B., London E.D. Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase. Psychopharmacology. 112:1993;521-524.
31. G-nitro-L-arginine prevents morphine tolerance. Eur. J. Pharmacol. 221:1992;399-400.
32. Kolesnikov Y.A., Pick C.G., Ciszewska G., Pasternak G.W. Blockade of tolerance to morphine but not to κ-opioids by a nitric oxide synthase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 90:1993;5162-5166.
33. Lee J., Kim S.W., Kook H., Kang D.G., Kim N.H., Choi K.C. Effects of L-arginine on cyclosporin-induced alterations of vascular NO/cGMP generation. Nephrol. Dial. Transplant. 14:1999;2634-2638.
34. Licinio J., Prolo P., McCann S.M., Wong M.L. Brain iNOS: current understanding and clinical implications. Mol. Med. Today. 5:1999;225-232.
35. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:1991;807-815.
36. L'opez-ongil S., Saura M., Rodr'iguez-puyol D., Rodr'iguez-puyol M., Lamas S. Regulation of endothelial NO synthase expression by cyclosporin A in bovine aortic endothelial cells. Am. J. Physiol. 271:1996;H1072-H1078.
37. Lyons W.E., George E.B., Dawson T.M., Steiner J.P., Snyder S.H. Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc. Natl. Acad. Sci. U. S. A. 91:1994;3191-3195.
38. Machelska H., Labuz D., Przewlocki R., Przewlocka B. Inhibition of nitric oxide synthase enhances antinociception mediated by Mu, Delta and Kappa opioid receptors in acute and prolonged pain in the rat spinal cord. J. Pharmacol. Exp. Ther. 282:1997;977-984.
39. Magazine H.I., Liu Y., Bilfinger T.V., Frichionne G.L., Stefano G.B. Morphine-induced conformational changes in human monocytes, granulocytes, and endothelial cells and in invertebrate immunocytes and microglia are mediated by nitric oxide. J. Immunol. 156:1996;4845-4850.
40. Majeed N.H., Przewlocka B., Machelska H., Przewlocki R. Inhibition of nitric oxide synthase attenuates the development of morphine tolerance and dependence in mice. Neuropharmacology. 33:1994;189-192.
41. Mathieu P., Carrier M., Dupuis J., Ryan J., Pelletier L.C. L-arginine prevents cyclosporin A-induced pulmonary vascular dysfunction. Ann. Thorac. Surg. 64:1997;414-420.
42. McVaugh W., Lawrence B., Kulkarni A., Pizzini R., Van Buren C., Rudolph F., Wolinsky I., Dafny N. Suppression of opiate withdrawal by cyclosporin A and dietary modification. Life Sci. 44:1989;977-983.
43. Meller S.T., Gebhart G.F. Nitric oxide (NO) nociceptive processing in the spinal cord. Pain. 52:1993;127-136.
44. Nahavandi A., Mani A.R., Homayounfar H., Akbari M.R., Dehpour A.R. The role of the interaction between endogenous opioids and nitric oxide in the pathophysiology of ethanol-induced gastric damage in cholestatic rats. Fundam. Clin. Pharmacol. 15:2001;181-187.
45. Pataki I., Telegdy G. Further evidence that nitric oxide modifies acute and chronic morphine actions in mice. Eur. J. Pharmacol. 357:1998;157-162.
46. Prevot V., Rialas J.C., Croix D., Salzet M., Dupouy J.P., Puolain P., Beauvillain J.C., Stefano G.B. Morphine and anadamide coupling to nitric oxide stimulated GnRH and CRF release from rat median eminence: neurovascular regulation. Brain Res. 790:1998;236-244.
47. Przewlocki R., Machelska H., Przewlocka B. Inhibition of nitric oxide synthase enhances morphine antinociception in the rat spinal cord. Life Sci. 53:1993;PL1-PL5.
48. Rao M.R., Kanji V.K., Salahudeen M.K., Wang C., Sekhar V. Inhibition of rat brain nitric oxide synthase activity by cyclosporin-A. Indian J. Exp. Biol. 34:1996;1265-1267.
49. Rao M.R., Kanji V.K., Setty V.V., Wang C., Salahudeen A.K., Das S.K., Cohly H.H. Cyclosporin A-induced changes in nitric oxide synthase activity in the rat kidney: invitro and in vivo assay. Indian J. Physiol. Pharmacol. 40:1996;183-185.
50. Ruiz F., Alvarez G., Ramos M., Hernandez M., Bogonez E., Satrustegui J. Cyclosporin A targets involved in protection against glutamate excitotoxicity. Eur. J. Pharmacol. 404:2000;29-39.
51. Sabatini D.M., Lai M.M., Snyder S.H. Neural roles of immunophilins and their ligands. Mol. Neurobiol. 15:1997;223-239.
52. Sanchez-Lozada L.G., Gamba G., Bolio A., Jimenez F., Herrera-Acosta J., Bobadilla N.A. Nifedipine prevents changes in nitric oxide synthase mRNA levels induced by cyclosporine. Hypertension. 36:2000;642-647.
53. Sharkey J., Butcher S.P. Immunophilins mediate the immunoprotective effects of FK506 in focal cerebral ischaemia. Nature. 371:1994;336-339.
54. Snyder S.H., Sabatini D.M., Lai M.M., Steiner J.P., Hamilton G.S., Suzdak P.D. Neural actions of immunophilin ligands. Trends Pharmacol. Sci. 19:1998;21-26.
55. Sousa A.M., Prado W.A. The dual effect of a nitric oxide donor in nociception. Brain Res. 897:2001;9-19.
56. Stefano G.B., Salzet B., Rialas C.M., Pope M., Kustka A., Neenan K., Pryor S.C., Salzet M. Morphine and anandamide stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res. 763:1997;63-68.
57. Stefano G.B., Goumon Y., Bilfinger T.V., Welters I.D., Cadet P. Basal nitric oxide limits immune, nervous and cardiovascular excitation: human endothelia express a mu opiate receptor. Prog. Neurobiol. 60:2000;513-530.
58. Steiner J.P., Dawson T.M., Fotuhi M., Glatt C.E., Snowman A.M., Cohen N., Snyder S.H. High brain densities of immunophilin FKBP colocalized with calcineurin. Nature. 358:1992;584-587.
59. Steiner J.P., Dawson T.M., Fotuhi M., Snyder S.H. Immunophilin regulation of neurotransmitter release. Mol. Med. 2:1996;325-333.
60. Stroes E.S., Luscher T.F., De Groot F.G., Koomans H.A., Rabelink T.J. Cyclosporin A increases nitric oxide activity in vivo. Hypertension. 29:1997;570-575.
61. Suzuki H., Wolf W.P., Akiyama K., Horstman D., Grant P., Cannavino C., Bing R.J. Effect of inhibitors of inducible form of nitric oxide synthase in infarcted heart muscle. Proc. Assoc. Am. Physicians. 108:1996;173-178.
62. Taylor D.A., Fleming W.W. Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. J. Pharmacol. Exp. Ther. 297:2001;11-18.
63. Thompson S.J., Koszdin K., Bernards C.M. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology. 92:2000;1392-1399.
64. G-monomethyl-L-arginine and MK-801 on the abstinence syndrome in morphine-dependent mice. Brain Res. 642:1994;153-159.
65. Vaupel D.B., Kimes A.S., London E.D. Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Neuropsychopharmacology. 13:1995;315-322.
66. Way E.L., Loh H.H., Shen F.H. Simultanous quantitative assessment of morphine tolerance and physical dependence. J. Pharmacol. Exp. Ther. 167:1969;1-8.
67. Wüster M., Schulz R., Herz A. Opioid tolerance and dependence: Re-evaluating the unitary hypothesis. Trends Pharmacol. Sci. 6:1985;64-67.